Table 1 Baseline characteristics of participants.
Phenotypes | Study | Source | Total (n) | Men (%) | Age mean (SD) | Crude mean (SD) (ng/mL) |
|---|---|---|---|---|---|---|
Exposure | ||||||
Vitamin D | JPHC-base | Population-based cohort | 3739 | 34.0 | 53.8 (7.8) | 22.0 (7.1) |
Vitamin D | J-MICC | Population-based cohort | 239 | 25.1 | 58.5 (9.7) | 18.0 (5.1) |
Outcome | Study | Source | Case/Control (n) | Men (%) | Age Mean (SD) among case | Age Mean (SD) among control |
|---|---|---|---|---|---|---|
Total cancer | JPHC-base | Population-based cohort | 3541/10,536 | 54.1/35.1 | 56.8 (7.5) | 53.9 (7.9) |
Total cancer | JPHC-5 year | Population-based cohort | 1002/3688 | 61.1/41.7 | 55.2 (6.8) | 52.9 (7.4) |
All (total cancer) | 4543/14,224 | |||||
Colorectal cancer | JPHC-base | Population-based cohort | 482/2434 | 51.0/35.0 | 57 (7.3) | 53.8 (7.9) |
Colorectal cancer | JPHC-5 year | Population-based cohort | 194/3607 | 57.7/41.4 | 55.5 (6.8) | 52.8 (7.4) |
Colorectal cancer | J-MICC | Population-based cohort | 300/901 | 62.0/49.4 | 60.0 (6.5) | 55.4 (10.0) |
Colorectal cancer | NAGANO | Hhospital-based case–control | 105/103 | 62.9/63.1 | 59.4 (9.0) | 59.2 (8.8) |
Colorectal cancer | HERPACC | Hospital-based case–control | 163/3819 | 63.2/49.5 | 59.4 (10.1) | 52.1 (12.2) |
Colorectal cancer | BBJ | Hospital-based case–control | 6692/27,178 | 63.7/39.3 | 66.9 (10.1) | 60.7 (10.0) |
All (Colorectal cancer) | 7936/38,042 |
